NCT04254107 2025-02-10A Safety Study of SEA-TGT (SGN-TGT) in Advanced CancerSeagen Inc.Phase 1 Terminated133 enrolled
NCT01990534 2021-04-09A Study of Brentuximab Vedotin in Participants With Relapsed or Refractory Hodgkin LymphomaTakedaPhase 4 Completed60 enrolled 21 charts
NCT01925612 2018-06-21Study of Brentuximab Vedotin Combined With RCHOP or RCHP in Front-line Treatment of Patients With Diffuse Large B-cell Lymphoma (DLBCL)Seagen Inc.Phase 2 Terminated87 enrolled 18 charts
NCT01421667 2016-11-28A Study of Brentuximab Vedotin in Relapsed or Refractory Non-Hodgkin LymphomaSeagen Inc.Phase 2 Completed176 enrolled 30 charts